Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
calcitriol, Quantity: 0.25 microgram
Strides Pharma Science Pty Ltd
Calcitriol
Capsule, soft
Excipient Ingredients: butylated hydroxyanisole; iron oxide red; purified water; Gelatin; iron oxide yellow; fractionated coconut oil; glycerol; sorbitol solution (70 per cent) (non-crystallising); butylated hydroxytoluene
Oral
100 capsules
(S4) Prescription Only Medicine
Calciprox is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture. Calciprox is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss. Calciprox is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.
Visual Identification: Red coloured, oval, soft-gelatin capsules containing a clear, oily liquid.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius
Registered
2008-09-25
calcitriol 0.25 microgram capsules Calciprox ™ Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Calciprox™ capsules. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Calciprox™ capsules against the benefits they expect it will have for you. If you have any concerns about taking this medicine, ask your doctor or pharmacist. Keep this leaflet with the medicine. You may need to read it again. What Calciprox™ is used for Calciprox™ contains the active ingredient calcitriol, one of the naturally occurring and biologically active forms of Vitamin D. Calcitriol acts in the body in a similar manner to Vitamin D. Calciprox™ is used to treat people with osteoporosis, a disease where the bones of the body weaken, and in the prevention of osteoporosis in people taking oral corticosteroids. Calciprox™ capsules are also prescribed for patients who have low blood calcium levels due to osteodystrophy (a type of bone disease), hypoparathyroidism (a condition where the parathyroid glands have decreased function) and rickets. Calciprox™ increases calcium absorption in the intestine and stimulates healthy bone growth. There are many different types of medicines used to treat bone conditions. Calciprox™ belongs to a group of medicines known as vitamin D compounds. Your doctor may have prescribed Calciprox™ for another purpose. Ask your doctor if you have any questions why Calciprox™ has been prescribed for you. This medicine is available only with a doctor’s prescription. Calciprox™ is not addictive. Before you take Calciprox™ When you must not take it Do not take Calciprox™ if: You have had an allergic reaction to Calciprox™, calcitriol or any ingredients listed in the Ingredients section of this leaflet You have high blood calcium levels (hypercalcaemia) You have vitamin D toxicity Read the complete document
Page 1 of 11 PRODUCT INFORMATION CALCIPROX TM CAPSULES _ _ NAME OF THE MEDICINE _ _ The active ingredient in CALCIPROX TM is Calcitriol._ _ The structural formula is: CAS 32222-06-3 Chemical name: (5_Z_,7_E_)-9,10-secocholesta-5,7,10(19)-triene-1α,3β,25-triol (calcitriol) Molecular formula: C 27 H 44 O 3 . Calcitriol has a molecular weight of 416.65. _ _ DESCRIPTION Calcitriol is a white, crystalline compound, which occurs naturally in humans. It is soluble in organic solvents but practically insoluble in water. Calcitriol is available as soft gelatin capsules containing 0.25 micrograms of calcitriol. Each capsule also contains butylated hydroxyanisole, butylated hydroxytoluene, coconut oil - fractionated, gelatin, glycerol, sorbitol (70 percent, non-crystallising), iron oxide red and iron oxide yellow. PHARMACOLOGY _ _ _PHARMACODYNAMICS: _Calcitriol is the most important active metabolite of vitamin D 3 . It is normally formed in the kidney from its precursor 25-hydroxycholecalciferol (25-HCC). Physiological daily production is normally 0.5 - 1.0 g and is somewhat higher during periods of increased bone synthesis (eg growth or pregnancy). The natural supply of vitamin D in humans depends mainly on exposure to ultraviolet rays of the sun for conversion of 7-dehydrocholesterol in the skin to vitamin D 3 (cholecalciferol). Vitamin D 3 must be metabolically activated in the liver and the kidney before it is fully active as a regulator of calcium and phosphorus metabolism at target tissues. The initial transformation of vitamin D 3 is Page 2 of 11 catalysed by a vitamin D 3 -25-hydroxylase enzyme (25-OHase) present in the liver, and the product of this reaction is 25-hydroxyvitamin D 3 [25-(OH) D 3 ]. Hydroxylation of 25-(OH) D 3 occurs in the mitochondria of kidney tissue, activated by the renal 25-hydroxyvitamin D 3 -1 alpha-hydroxylase (alpha-OHase), to produce 1,25-(OH)2 D 3 (calcitriol), the active form of vitamin D 3 . Calcitriol binds to an intracellular receptor, a member of the steroid receptor superfa Read the complete document